Highlights from Day 2 of the ESC 2021 congress – APAF-CRT

By Ahmed El-Medany Presented by Professor Michele Brignole, San Luca Hospital, Milan, APAF-CRT was a two-phase trial in individuals with severely symptomatic atrial fibrillation (AF)…

View More Highlights from Day 2 of the ESC 2021 congress – APAF-CRT

Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF

The ENVISAGE-TAVI AF trial demonstrated that Edoxaban’s non-inferiority to warfarin with regards to myocardial infarction (MI), ischaemic stroke, systemic thromboembolism, and valve thrombosis, in participants…

View More Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF

Highlights from Day 2 of the ESC 2021 congress – MASTER DAPT

Presented by Dr. Marco Valgimigli, the MASTER DAPT trial assessed whether 1 month of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), with a…

View More Highlights from Day 2 of the ESC 2021 congress – MASTER DAPT
Pacemaker

Impaired retinal microvascular function predicts long-term adverse events in patients with cardiovascular disease

By Theuerle JD, Al-Fiadh AH et al Endothelial dysfunction is a precursor to the development of symptomatic atherosclerosis. Retinal microvascular reactivity to flicker light stimulation…

View More Impaired retinal microvascular function predicts long-term adverse events in patients with cardiovascular disease